This meta-analysis quantifies initiation and discontinuation rates for oral and depot naltrexone in opioid use disorder, finding that supervised administration significantly reduces early discontinuation of oral formulations.
A meta-analysis suggests that clinical trials for alcohol use disorder medications lasting 12 weeks or less may be as effective as longer trials, challenging current FDA recommendations for six-month study durations.
A Swedish study published in Nature Medicine indicates that repurposing a Parkinson's medication as an add-on therapy may alleviate motivation and anhedonia symptoms in patients with treatment-resistant depression.
Lumateperone is associated with a reduced risk of relapse in patients with schizophrenia, supporting its efficacy as a maintenance treatment.
Community-level increases in buprenorphine treatment initiation and long-term retention are significantly associated with reduced opioid overdose mortality rates.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Jun 11 – Jun 13)
- Consider adding pramipexole as an augmentation strategy for patients with mood disorders who have persistent anhedonia and motivation deficits.
- Lumateperone demonstrates efficacy as a maintenance treatment for schizophrenia by significantly reducing relapse risk.
- When prescribing oral naltrexone for opioid use disorder, utilize supervised administration to significantly reduce early discontinuation rates.
- Advocate for community-level expansion of buprenorphine initiation and retention programs to achieve measurable reductions in opioid overdose mortality.
- Minimize antipsychotic doses when planning tDCS therapy for schizophrenia to avoid negating cognitive improvements associated with neuromodulation.
- Reevaluate the necessity of prolonged 6-month clinical trials for alcohol use disorder medications, as shorter durations may yield comparable efficacy.
- Monitor patients on repurposed Parkinson's medications closely for potential alleviation of treatment-resistant depression symptoms, particularly regarding motivation and anhedonia.
- Consider psilocybin-assisted therapy as a viable pharmacotherapeutic option for patients with treatment-resistant depression who have failed standard interventions.
Clinical Pearl 1
A randomized controlled trial demonstrates that the dopamine agonist pramipexole significantly reduces anhedonia in patients with mood disorders when used as an augmentation strategy.
Diagnosis & Treatment 2
Higher antipsychotic doses negatively correlate with cognitive improvements from tDCS in schizophrenia, suggesting that minimizing pharmacological burden may optimize neuromodulation efficacy.
Real-world data indicates psilocybin offers clinical benefit for treatment-resistant depression, supporting its potential role in psychiatric pharmacotherapy.